Selected References:

• Arango O, et al. 1996. Reversible azoospermia in a patient treated with triazolam. Eur J Contracept Reprod Health Care; 1:293-4.
• Bagger NT, et al. 2023. Perinatal outcomes after therapeutic rest in the latent phase of labor: A cohort study. Acta obstetricia et gynecologica Scandinavica, 102(9), 1210–1218.
• Halcion Prescribing Information. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017892s049lbl.pdf. [Accessed Jan 2025]
• Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. Pharmaceuticals 6(10):1221-1286.
• Kelly LE, et al. 2012. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr; 161(3):448-51.
• Matsuo A, et al. 1979. Reproduction studies of triazolam in rats and rabbits. Iyakuhin Kenkyu 10:52-67.
• Noh Y, et al. 2022. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. PLoS Med; 19(3):e1003945.
• Sakai T, et al. 1996. Triazolam (Halcion) intoxication in a neonate–a first report [letter]. Eur J Pediatr; 155:1065-6.

Selected References:

• Aselton P, et al. 1984. First-trimester drug use and congenital disorders. Obstet Gynecol,65(4):451- 455.
• Brigstocke S, et.al 2022. Review of the Safety Profiles of Laxatives in Pregnant Women. J Clin Gastroenterol, 56(3):197-203.
• Greenhalf JO, Leonard HS. 1973. Laxatives in the treatment of constipation in pregnant and breast-feeding mothers. Practitioner; 210:259-63.
• Hale, TW. 2012. Medications and Mothers’ Milk. Fifteenth Edition. Amarillo, TX: Hale Publishing L.P.
• Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Littleton, Mass.: John Wright-PSG, pp 385, 442.
• Jick H, et al. 1981. First-trimester drug use and congenital disorders. JAMA,246(4):343-346.
• Laden S. 2019. OTC Medication Use in Pregnancy and Breastfeeding. US Pharmacist, 44(9):16-19
• Lameris AL, et al. 1979. Drug induced alterations in Mg2+ homeostasis. Clinical Science,123(1):1.
• MacKenzie K, et al. 1990. Three-generation reproduction study with dioctyl sodium sulfosuccinate in rats. Fundam Appl Toxicol,15:53-62.
• Mahadevan U, & Kane S. 2006. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology,131(1):283-311.
• Rungsiprakarn P, et al. 2015. Interventions for treating constipation in pregnancy. Cochrane Database Syst Rev, Sep 4;2015(9):CD011448
• Schindler AM. 1984. Isolated neonatal hypomagnesaemia associated with maternal overuse of stool softener. Lancet,2:822.
• Thorpe PG, et al. 2013. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Safe, 22(9): 1013-1018.
• Zielinski R, et al. 2015. Gastrointestinal distress in pregnancy: prevalence, assessment, and treatment of 5 common minor discomforts. J Perinat Neonatal Nurs, 29(1):23-31.

Selected References:

• American Academy of Pediatrics. 2008. Maternal phenylketonuria. Committee on Genetics. Pediatrics;122:445–9.
• American College of Obstetricians and Gynecologists Committee on Genetics. 2020. ACOG Committee Opinion 802: Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria). Obstet Gynecol. 135(4):e167-e170.
• Aldámiz-Echevarría L,et al. 2014. A new case of maternal phenylketonuria treated with sapropterin dihydrochloride. Gynecol Endocrinol. 13:1-3.
• Banta-Wright SA, et al. 2014. Breastfeeding infants with phenylketonuria in the United States and Canada. Breastfeeding Medicine, 9(3), 142-148.
• Burgard P, et al. 1997. Neuropsychologic functions of early treated patients with phenylketonuria, on and off Diet: Results of a cross-national and cross-sectional study. Pediatr Res 41(3):368-374.
• Camp KM, et al. 2014. Phenylketonuria Scientific Review Conference: state of the science and future research needs. Mol Genet Metab. 112(2):87-122.
• Cetin I, et al. 1990. Umbilical amino acid concentration in normal and growth-retarded fetuses sampled in utero by cordocentesis. Am J Obstet Gynecol; 162(1):253–261.
• Feillet F, et al. 2014. Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases.J Inherit Metab Dis.
• Fisch RO, et al. 1991. Children of fathers with phenylketonuria: An international survey. J Pediatr 118(5): 39-741.
• Fox-Bacon C, et al. 1997. Maternal PKU and breastfeeding: case report of identical twin mothers. Clin Pediatr 36(9):539-542.
• Grange DK,et al. 2014. Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry. Phenylketonuria Demographics Outcomes and Safety (PKUDOS) registry; Maternal Phenylketonuria Observational Program (PKU MOMS) sub-registry. Mol Genet Metab. 112(1):9-16.
• Grohmann-Held K, et al. 2022. Impact of pregnancy planning and preconceptual dietary training on metabolic control and offspring’s outcome in phenylketonuria. J Inherit Metab Dis; 45( 6): 1070- 1081.
• Güttler F, et al. 1990. Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. J Inherit Metab Dis. 13(4):665-71.
• Kenneson A, Borth MI, et al. 2024. Characteristics and outcomes of pregnancies among women with phenylketonuria from the NBS Connect registry. Mol Genet Metab Rep; 39:101092.
• Koch R, et al. 2003. The Maternal Phenylketonuria International Study: 1984–2002. Pediatrics 112(suppl): 1523-1529.
• Koch R, el al. 2005. Tetrahydrobiopterin and maternal PKU. Mol Gen Met 86: S139-S141.
• Koch R, et al. 2010. Psychosocial issues and outcomes in maternal PKU. Mol Genet Metab. 99 Suppl 1:S68-74.
• Kose E, et al. 2017. The effects of breastfeeding in infants with Phenylketonuria. J Pediatr Nurs; 38:27-32.
• Lenke RR and Levy HL. 1980. Maternal phenylketonuria and hyperphenylalanemia: An international survey of the outcome of untreated and treated pregnancies. NEJM 303(21):1202-1208.
• Levy HL, et al. 1991. Paternal phenylketonuria. J Pediatr 118(5):741-743.
• Levy HL, et al. 1996. Fetal ultrasonagraphy in maternal PKU. Prenat Diagn 16:599-604.
• Levy HL & Ghavami M. 1996. Maternal phenylketonuria: a metabolic teratogen. Teratology. 53(3):176-84.
• Lichter-Konecki, U, et al. 2019. Phenylketonuria: Current Treatments and Future Developments. Drugs 79, 495–500
• Maillot, F, et al. 2007. A practical approach to maternal phenylketonuria management. J Inherit Metab Dis. 30, 198–201.
• Michals-Matalon K et al. 2003. Role of nutrition in pregnancy with phenylketonuria and birth defects. Pediatrics 112(suppl): 1534-1536.
• Nielsen MR, Jørgensen C, et al. 2023. The impact of phenylalanine levels during pregnancy on birth weight and later development in children born to women with phenylketonuria. J Inherit Metab Dis; 46(4):586-594.
• Platt LD, et al. 2000. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. American journal of obstetrics and gynecology, 182(2), 326-333.
• Prick BW, et al. 2012. Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies. Am J Clin Nutr 95:374–382.
• Rouse B, et al. 1997. Maternal phenylketonuria Collaborative Study (MPUCS) offspring: Facial anomalies, malformations, and early neurological sequelae. Am J Med Genet 69:89-95.
• Rouse B & Azen C. 2004. Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. J Pediatr 144:235–239.
• Schmidt E, et al. 1994. Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood level. J Clin Exp Neuropsych 16(5):681-688.
• Singh RH, et al. 2014. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med 16:121–123.
• Smith WE, Berry SA, et al. 2025. Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med; 27(1):101289.
• Teissier R, et al. 2012. Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation. AFDPHE (Association Française pour le Dépistage et la Prévention des Handicaps de l’Enfant). J Inherit Metab Dis ;35:993–9.
• Trefz FK, et al. 2003. Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. Pediatrics 112(suppl): 1566-1569.
• Van Rijn M, et al. 2003. A different approach to breast-feeding of the infant with phenylketonuria. Eur J Pediatr 162:323-326.
• van Wegberg, A.M.J., et al. 2017. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis (12) 162.
• Vockley J, et al. 2014. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genetics in Medicine, 16(2), 188.
• Waisbren SE, et al. 2014. Maternal phenylketonuria: long-term outcomes in offspring and post-pregnancy maternal characteristics. In JIMD Reports, Volume 21 (pp. 23-33).
• Wambach K & Riordan J. 2016. Breastfeeding and human lactation. Jones & Bartlett Learning.
• Weglage J, et al. 2001. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res 49:532–536.
• Widaman KF, Azen C. 2003. Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. Pediatrics;112:1537–43.

Selected References:  

• Alsenaid A, Prinz JC. 2016. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 30(3):488-90.  
• American Academy of Pediatrics. 2018. Report of the Committee of Infectious Disease. RedBook. p704.  
• Andrulonis R, Ferris LK. 2012 Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 11(10):1240. 
• Avni-Biron, I.,et al. 2022. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study. Alimentary pharmacology & therapeutics, 56(9), 1361–1369.  
• Beaulieu D, et al. 2018. Use of Biologic Therapy by Pregnant Women with Inflammatory Bowel Disease does Not affect Infant Response to Vaccines. Clin Gast & Hep; 16:99-105. 
• Chaparro Sanchez M, et al. 2022. Live vaccines in children exposed to biological agents for IBD in utero and/or during breastfeeding: Are they safe? Results from the Dumbo registry of GETECCU. United European Gastroenterol J 2022;10:757-8.  
• Chugh, R., et al. 2024. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry. The American journal of gastroenterology, 119(3), 468–476.  
• Ernest-Suarez, K., et al. 2024. Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, S1542-3565(24)00677-3.  
• Fitzpatrick, T., et al. 2023. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. The Lancet. Child & adolescent health, 7(9), 648–656. 
• Fotiadou C, et al. 2012. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 6(4):105-107.Galli-Novak E, et al. 2016. Successful pregnancy outcome under prolonged ustekinumab treatment in a patientwith Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 30(12):e191-e192.   
• Galluzzo M, et al. 2019. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatolog Treat. 2019 Feb;30(1):40-44. 
• Gisbert J, Chaparro M. 2020. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. Drugs 2020 Jul; 80(11):1085-1100. 
• Gorodensky, J. H., Bernatsky, S., Afif, W., St-Pierre, Y., Filion, K. B., & Vinet, É. (2023). Assessing Serious Infections in Children Exposed In Utero to Ustekinumab. The Journal of rheumatology, jrheum.2022-1271.  
• Gotestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 75:795-810.  
• Grosen, A., et al. 2022. Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. Inflammatory bowel diseases, 28(10), 1603–1606.  
• Jeong, Y. D. et al. 2024. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study. International archives of allergy and immunology, 1–15.  
• Julsgaard, M., et al. 2025. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 23(1), 134–143.  
• Klenske E, et al. 2019. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn’s Disease. J Crohns Colitis. 2019 Feb 1;13(2):267-269. 
• Lund T and Thomsen SF. 2017. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. Dermatologic Therapy 30:e12454. 
• Mahadevan U, et al. 2017. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. Gastroenterology. 152(2):451-462.e2. 
• Mahadevan U, et al. 2019. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Amer J of Obstetrics and Gynecology. 2019 April; 220(4):308-323. 
• Mahadevan, U., et al. 2022. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer’s global safety database. Alimentary pharmacology & therapeutics, 56(3), 477–490. https://doi.org/10.1111/apt.16960 
• Martin PL, et al. 2010. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 89(5):351-363.  
• Matro R, et al. 2018. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel disease and effects of breastfeeding on infections and development. Gastroenterology 155;696-704. 
• Meserve, J., 2021. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology, 161(1), 107–115.e3.  
• Meyer, A., et al. 2025. Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 23(1), 144–153.e22.  
• Mitrova, K., et al. 2022. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. Journal of Crohn’s & colitis, 16(12), 1808–1815.  
• Prentice, R., et al. 2025. Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 23(1), 124–133.e7 
• Rocha K, et al. 2015. Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology; 231:103-104. 
• Rosen M, et al. 2012. A case of ustekinumab for the treatment of Crohn’s disease during pregnancy [abstract]. Amer J Gastroenterol. 107(suppl 1):S516. 
• Rowan CR, et al. 2018. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s Disease treated until 33 weeks of gestation. Journal of Crohn’s and Colitis;376-378 
• Sánchez-García, V., et al. 2023. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology : JEADV, 37(10), 1971–1990.  
• Sheeran C, Nicolopoulos J. 2014. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australasian J of Dermatology; 55(3);235-236. 
• Wils P, et al. 2021. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther; 53(4):460-470. 

Selected References:

• Anderson JL, et. al. 2014. Congenital lymphocytic choriomeningitis virus: when to consider the diagnosis. J Child Neurol 29(6):837-42.
• Barton LL and Mets MB. 2001. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. CID 33:370-374.
• Barton LL, et al. 1995. Lymphocytic choriomeningitis virus: an unrecognized teratogenic pathogen. Emerg Infect Dis 1(4):152-153.
• Bonthius DJ. 2009. Lymphocytic choriomeningitis virus: a prenatal and postnatal threat. Advances in Pediatrics 56:75-86.
• Bonthius DJ. 2012. Lymphocytic choriomeningitis virus: An underrecognized cause of neurologic disease in the fetus, child and adult. Semin Pediatr Neurol 19:89-95.
• Bonthius DJ. 2024. Lymphocytic choriomeningitis virus injures the developing brain: effects and mechanisms. Pediatr Res 95(2):551-557.
• Centers for Disease Control and Prevention. 2014. Lymphocytic choriomeningitis. [Accessed 2/2021]. Available at URL: https://www.cdc.gov/vhf/lcm/ and https://www.cdc.gov/vhf/lcm/pdf/factsheet.pdf.
• Childs JE, et al. 1992. Lymphocytic choriomeningitis virus infection and house mouse (Mus musculus) distribution in urban Baltimore. Am J Trop Med Hyg 47(1):27-34.
• Delaine M, et al. 2017. Microcephaly caused by lymphocytic choriomeningitis virus. Emerg Infect Dis 23(9):1548-1550.
• Enninga AA, et al. 2019. Lymphocytic Choriomeningitis Virus Infection Demonstrates Higher Replicative Capacity and Decreased Antiviral Response in the First-Trimester Placenta. J Immunol Res. Feb 7;2019:7375217. doi: 10.1155/2019/7375217. eCollection 2019.
• Ferenc T,et al. Lymphocytic choriomeningitis virus: An under-recognized congenital teratogen. World J Clin Cases. 2022 Sep 6;10(25):8922-8931.
• Fortin O, et al. 2024. Congenital infectious encephalopathies from the intrapartum period to postnatal life. Semin Fetal Neonatal Med. Epub 2024 Apr 10. PMID: 38677956.
• Hirsch MS, et al. 1974. Lymphocytic-choriomeningitis-virus infection traced to a pet hamster. NEJM 291(12):610-611.
• Jamieson D, et al. 2005. Lymphocytic choriomeningitis virus: An emerging obstetric pathogen. Am J Obstet Gynecol 194:1532-1536.
• Komrower GM, et al. 1955. Lymphocytic choriomeningitis in the newborn: probable transplacental infection. Lancet 1:697-698.
• Meritet JF, et al. 2009. A case of congenital lymphocytic choriomeningitis virus infection revealed by hydrops fetalis. Prenatal Diagnosis 20:626-627.
• Olivieri NR, et al. 2024. Transmission, seroprevalence, and maternal-fetal impact of lymphocytic choriomeningitis virus. Pediatr Res; 95(2):456-463.
• Pencole L, et al. Congenital lymphocytic choriomeningitis virus: A review. Prenat Diagn. 2022 Jul;42(8):1059-1069.
• Schulte D, et al. 2006. Congenital lymphocytic choriomeningitis virus: an underdiagnosed cause of neonatal hydrocephalus. The Pediatric Infectious Disease Journal 25(6):560-562.
• Tevaearai F, Moser L, Pomar L. Prenatal Diagnosis of Congenital Lymphocytic Choriomeningitis Virus Infection: A Case Report. Viruses. 2022 Nov 21;14(11):2586
• Traube E. 1973. LCM Virus research, retrospect and prospects, in Lymphocytic Choriomeningitis Virus and Other Arenaviruses, Lehmann-Grube F. (ed.) Berlin: Springer-Verlag, pp.3-10.
• Wright R, et al. 1997. Congenital lymphocytic choriomeningitis virus syndrome: A disease that mimics congenital toxoplasmosis or cytomegalovirus. Pediatrics 100(1):1-6.